应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
GRCL 亘喜生物
停牌 07-05 07:14:26 EDT
10.25
+0.00
0.00%
最高
10.25
最低
10.25
成交量
0.00
今开
10.25
昨收
10.25
日振幅
0.00%
总市值
9.91亿
流通市值
3.41亿
总股本
9,671万
成交额
6,573万
换手率
0.00%
流通股本
3,328万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
EHA观察|加入阿斯利康后再次公开亮相,亘喜生物继续“上分”
氨基观察 · 06-18
EHA观察|加入阿斯利康后再次公开亮相,亘喜生物继续“上分”
被阿斯利康并购后,亘喜生物要进行细胞治疗药物扩产
第一财经 · 06-17
被阿斯利康并购后,亘喜生物要进行细胞治疗药物扩产
130亿的并购,投资人俩月赚4倍
华尔街见闻 · 04-10
130亿的并购,投资人俩月赚4倍
俩月赚4倍,最快退出诞生了
投中网 · 04-08
俩月赚4倍,最快退出诞生了
一家B轮公司,卖了130亿
蓝鲸财经 · 04-07
一家B轮公司,卖了130亿
亘喜生物并入阿斯利康 将从纳斯达克退市
北京商报 · 02-23
亘喜生物并入阿斯利康 将从纳斯达克退市
亘喜生物并入阿斯利康集团,将从纳斯达克退市
界面 · 02-23
亘喜生物并入阿斯利康集团,将从纳斯达克退市
亘喜生物宣布公司股东正式投票表决通过了与阿斯利康的并购协议
GlobeNewswire · 02-20
亘喜生物宣布公司股东正式投票表决通过了与阿斯利康的并购协议
亘喜生物宣布FasTCAR-T GC012F早线治疗多发性骨髓瘤的1期新药临床试验(IND)申请获美国FDA批准
GlobeNewswire · 01-29
亘喜生物宣布FasTCAR-T GC012F早线治疗多发性骨髓瘤的1期新药临床试验(IND)申请获美国FDA批准
加载更多
公司概况
公司名称:
亘喜生物
所属市场:
NASDAQ
上市日期:
--
主营业务:
亘喜生物科技公司是一家获豁免的有限责任公司,于2018年5月22日在开曼群岛注册成立,是一家致力于发现和开发突破性细胞疗法的全球临床阶段生物制药公司。利用其开创性FasTCAR和TruUCAR技术平台,亘喜生物正在开发多项自体和同种异体的丰富临床阶段癌症治疗产品管线。这些产品有望攻克传统CAR-T疗法持续存在的重大行业挑战,包括生产时间长、产品细胞质量欠佳、治疗成本高和对实体瘤缺乏有效治疗等。
发行价格:
--
{"stockData":{"symbol":"GRCL","market":"US","secType":"STK","nameCN":"亘喜生物","latestPrice":10.25,"timestamp":1708549200000,"preClose":10.25,"halted":3,"volume":0,"delay":0,"floatShares":33278469,"shares":96712353,"eps":-0.950223,"marketStatus":"停牌","marketStatusCode":1,"change":0,"latestTime":"07-05 07:14:26 EDT","open":10.25,"high":10.25,"low":10.25,"amount":65729813.680143,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.950223,"exchange":"NASDAQ","tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1720186200000},"adr":0,"listingDate":1610082000000,"adjPreClose":10.25,"adrRate":5,"volumeRatio":0},"requestUrl":"/m/hq/s/GRCL","defaultTab":"news","newsList":[{"id":"2444017894","title":"EHA观察|加入阿斯利康后再次公开亮相,亘喜生物继续“上分”","url":"https://stock-news.laohu8.com/highlight/detail?id=2444017894","media":"氨基观察","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444017894?lang=zh_cn&edition=full","pubTime":"2024-06-18 11:16","pubTimestamp":1718680599,"startTime":"0","endTime":"0","summary":"ASCO年会之后,2024年欧洲血液学协会年会(EHA)接踵而来,各类创新成果同样精彩纷呈。作为欧洲血液学领域规模最大的国际盛会,每年都吸引着来自世界各地的专家学者到访。根据EHA官网发布的摘要统计,今年共有24篇来自中国的研究入选口头报告、184篇研究入选壁报展示以及127篇研究线上发表,同比增长27%。可以说,EHA2024继...","market":"us","thumbnail":"https://inews.gtimg.com/om_ls/Ow3TBMacKOYevWMbI-fbZBVCRuBJ-X4qsgmqAHDHmADuoAA_294195/0","type":0,"news_type":0,"thumbnails":["https://inews.gtimg.com/om_ls/Ow3TBMacKOYevWMbI-fbZBVCRuBJ-X4qsgmqAHDHmADuoAA_294195/0"],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20240618A033AZ00","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20240618A033AZ00","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent_tech","symbols":["LU0320765992.SGD","LU2236285917.USD","BK4535","BK4588","BK4585","GRCL","BK4007","LU1829250122.USD","LU0889565916.HKD","BK4568","BK4139","LU0109394709.USD","AZN"],"gpt_icon":0},{"id":"2444153268","title":"被阿斯利康并购后,亘喜生物要进行细胞治疗药物扩产","url":"https://stock-news.laohu8.com/highlight/detail?id=2444153268","media":"第一财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444153268?lang=zh_cn&edition=full","pubTime":"2024-06-17 16:15","pubTimestamp":1718612130,"startTime":"0","endTime":"0","summary":"去年年底,阿斯利康宣布以约12亿美元价格并购亘喜生物,后者成为了首家被跨国药企全资并购的中国生物科技企业。被并购后,亘喜生物在加码细胞治疗药物生产。近日,亘喜生物宣布,与苏州生物医药产业园正式签署合作备忘录。根据协议,亘喜生物将深化与苏州生物医药产业园的战略合作,进一步扩展生产空间,提升细胞治疗药物产能,进一步夯实阿斯利康细胞疗法领域实力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240617161705aef53cab&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240617161705aef53cab&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0889565916.HKD","BK4535","BK4588","LU1829250122.USD","BK4007","LU0109394709.USD","AZN","BK4568","GRCL","LU0320765992.SGD","BK4139","BK4585","LU2236285917.USD"],"gpt_icon":0},{"id":"2426649266","title":"130亿的并购,投资人俩月赚4倍","url":"https://stock-news.laohu8.com/highlight/detail?id=2426649266","media":"华尔街见闻","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2426649266?lang=zh_cn&edition=full","pubTime":"2024-04-10 21:48","pubTimestamp":1712756923,"startTime":"0","endTime":"0","summary":"B轮投资人在短短两个月后,就已经锁定退出,而且预计将获得超过4倍的收益,这无疑也是近年来的最快退出记录。","market":"hk","thumbnail":"https://wpimg-wscn.awtmt.com/7abf7205-b2eb-4790-903d-b3325384124d.png","type":0,"news_type":0,"thumbnails":["https://wpimg-wscn.awtmt.com/7abf7205-b2eb-4790-903d-b3325384124d.png"],"rights":{"source":"wallstreetcn_hot_news","url":"https://wallstreetcn.com/articles/3712431","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3712431","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"wallstreetcn_hot_news","symbols":["GRCL","BK4139","ADC","BK4535","BK4231","BK4080"],"gpt_icon":0},{"id":"2425954227","title":"俩月赚4倍,最快退出诞生了","url":"https://stock-news.laohu8.com/highlight/detail?id=2425954227","media":"投中网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2425954227?lang=zh_cn&edition=full","pubTime":"2024-04-08 16:31","pubTimestamp":1712565084,"startTime":"0","endTime":"0","summary":"130亿交易落地,这次轮到20多家投资机构庆祝了。前几日,创新药巨头Genmab发布公告称,将以18亿美元(约130亿人民币)全现金形式,收购普方生物(ProfoundBio)。这是自去年底以来,国内第四家被收购的ADC公司。也刷新了此前亘喜生物以12亿美元的价格卖给阿斯利康的纪录。根据公告信息显示,这笔收购将使 Genmab 获得三项处...","market":"hk","thumbnail":"https://inews.gtimg.com/om_ls/O3TOXYP29r8dVbCIpxIf8KLpdV0oFc-KxEzageUFAE-zMAA_294195/0","type":0,"news_type":0,"thumbnails":["https://inews.gtimg.com/om_ls/O3TOXYP29r8dVbCIpxIf8KLpdV0oFc-KxEzageUFAE-zMAA_294195/0"],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20240408A05ZKY00","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20240408A05ZKY00","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent_tech","symbols":["GRCL","BK4535","BK4139","BK4231","ADC","BK4080"],"gpt_icon":0},{"id":"2425669170","title":"一家B轮公司,卖了130亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2425669170","media":"蓝鲸财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2425669170?lang=zh_cn&edition=full","pubTime":"2024-04-07 16:45","pubTimestamp":1712479541,"startTime":"0","endTime":"0","summary":"一笔极具标杆性的并购诞生了。近日,丹麦药企Genmab以18亿美元的高价,并购普方生物。官网显示,普方生物是一家成立于2019年的临床阶段生物技术公司,由赵柏腾、韩泰熙、尚晓三位博士创立,开发了一系列针对多种肿瘤靶点的ADC药物产品管线。值得一提的是,三人此前均有在生物技术公司Seagen的工作经历,要知道作为ADC先驱,Seagen曾被辉瑞以430亿美元的“天价”收购而引人瞩目。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/230090","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK4139","GRCL","BK4535"],"gpt_icon":0},{"id":"2413734046","title":"亘喜生物并入阿斯利康 将从纳斯达克退市","url":"https://stock-news.laohu8.com/highlight/detail?id=2413734046","media":"北京商报","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2413734046?lang=zh_cn&edition=full","pubTime":"2024-02-23 17:09","pubTimestamp":1708679372,"startTime":"0","endTime":"0","summary":"2月23日,亘喜生物科技集团宣布正式完成了此前公告的与阿斯利康集团的合并协议。合并完成后,亘喜生物不再是一家上市公司,而成为母公司的全资子公司。公司已要求纳斯达克向美国证券交易委员会(SEC)提交25表格,通知SEC本公司将从纳斯达克退市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202402232993093120.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202402232993093120.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0320765992.SGD","SQQQ","BK4535","LU0889565916.HKD","NQmain","QQQ","BK1147","PSQ","BK4585","LU1829250122.USD","QID","ARTL","03086","AZN","BK4139","GRCL","LU0109394709.USD","BK4568","BK4007","MNQmain","QLD",".IXIC","NDX","TQQQ","LU2236285917.USD"],"gpt_icon":0},{"id":"2413330777","title":"亘喜生物并入阿斯利康集团,将从纳斯达克退市","url":"https://stock-news.laohu8.com/highlight/detail?id=2413330777","media":"界面","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2413330777?lang=zh_cn&edition=full","pubTime":"2024-02-23 15:54","pubTimestamp":1708674892,"startTime":"0","endTime":"0","summary":"2月22日,亘喜生物科技集团宣布正式完成了此前公告的与阿斯利康集团的合并协议。合并子公司是一家根据开曼群岛法律注册成立的豁免有限责任公司,也是母公司的全资子公司。此次合并中,合并子公司与亘喜生物进行合并,亘喜生物作为存续公司成为母公司的全资子公司。公司已要求纳斯达克向美国证券交易委员会提交25表格,通知SEC本公司将从纳斯达克退市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202402231554527a46053b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202402231554527a46053b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ARTL","LU0889565916.HKD","BK4535","TQQQ","LU0109394709.USD","AZN","QID",".IXIC","MNQmain","PSQ","NDX","BK4007","SQQQ","BK4139","LU0320765992.SGD","BK4568","GRCL","QLD","BK4585","NQmain","LU2236285917.USD","QQQ","LU1829250122.USD"],"gpt_icon":0},{"id":"2412017997","title":"亘喜生物宣布公司股东正式投票表决通过了与阿斯利康的并购协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2412017997","media":"GlobeNewswire","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2412017997?lang=zh_cn&edition=full","pubTime":"2024-02-20 12:45","pubTimestamp":1708404300,"startTime":"0","endTime":"0","summary":"公司宣布在2024年2月19日召开的特别股东大会上,经公司股东投票表决,通过了一项批准并授权公司正式执行、交付并履行此前于2023年12月23日宣布的拟议并购协议的提案。每位股东的每股普通股对应一票表决权。这些股份约占2024年1月8日开曼群岛收市时公司普通股总流通股所代表的投票权总数的94.8%。此次EGM,经股东投票表决,约99.9%的股东投票赞成该并购协议、合并计划以及交易。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/02/20/2831732/0/zh-hans/%E4%BA%98%E5%96%9C%E7%94%9F%E7%89%A9%E5%AE%A3%E5%B8%83%E5%85%AC%E5%8F%B8%E8%82%A1%E4%B8%9C%E6%AD%A3%E5%BC%8F%E6%8A%95%E7%A5%A8%E8%A1%A8%E5%86%B3%E9%80%9A%E8%BF%87%E4%BA%86%E4%B8%8E%E9%98%BF%E6%96%AF%E5%88%A9%E5%BA%B7%E7%9A%84%E5%B9%B6%E8%B4%AD%E5%8D%8F%E8%AE%AE.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRCL","BK4139","LU2236285917.USD","BK4007","LU0109394709.USD","LU0889565916.HKD","BK4585","BK4535","LU0320765992.SGD","LU1829250122.USD","AZN","BK4568"],"gpt_icon":0},{"id":"2407253852","title":"亘喜生物宣布FasTCAR-T GC012F早线治疗多发性骨髓瘤的1期新药临床试验(IND)申请获美国FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2407253852","media":"GlobeNewswire","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2407253852?lang=zh_cn&edition=full","pubTime":"2024-01-29 12:00","pubTimestamp":1706500800,"startTime":"0","endTime":"0","summary":"此次获批,是美国FDA授予GC012F的第三个IND批件。目前,公司正在开展FasTCAR-T GC012F的多项临床研究,适应症覆盖多种血液肿瘤和自身免疫性疾病。近日,美国FDA再次批准了GC012F早线治疗多发性骨髓瘤的IND申请。核心产品BCMA/CD19双靶点FasTCAR-T GC012F目前正处于一系列临床试验中,以探索其针对多发性骨髓瘤、B细胞非霍奇金淋巴瘤以及系统性红斑狼疮的治疗效果。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/01/29/2818739/0/zh-hans/%E4%BA%98%E5%96%9C%E7%94%9F%E7%89%A9%E5%AE%A3%E5%B8%83FasTCAR-T-GC012F%E6%97%A9%E7%BA%BF%E6%B2%BB%E7%96%97%E5%A4%9A%E5%8F%91%E6%80%A7%E9%AA%A8%E9%AB%93%E7%98%A4%E7%9A%841%E6%9C%9F%E6%96%B0%E8%8D%AF%E4%B8%B4%E5%BA%8A%E8%AF%95%E9%AA%8C-IND-%E7%94%B3%E8%AF%B7%E8%8E%B7%E7%BE%8E%E5%9B%BDFDA%E6%89%B9%E5%87%86.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1141","BK4139","BK1583","GRCL","BK1576","BK4535","03347"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.gracellbio.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0.0219},{"period":"1year","weight":1.6728},{"period":"ytd","weight":0.0209}],"compareEarnings":[{"period":"1week","weight":0.0109},{"period":"1month","weight":0.0448},{"period":"3month","weight":0.0748},{"period":"6month","weight":0.1785},{"period":"1year","weight":0.2426},{"period":"ytd","weight":0.1602}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"亘喜生物科技公司是一家获豁免的有限责任公司,于2018年5月22日在开曼群岛注册成立,是一家致力于发现和开发突破性细胞疗法的全球临床阶段生物制药公司。利用其开创性FasTCAR和TruUCAR技术平台,亘喜生物正在开发多项自体和同种异体的丰富临床阶段癌症治疗产品管线。这些产品有望攻克传统CAR-T疗法持续存在的重大行业挑战,包括生产时间长、产品细胞质量欠佳、治疗成本高和对实体瘤缺乏有效治疗等。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.15318},{"month":2,"riseRate":0.5,"avgChangeRate":-0.016645},{"month":3,"riseRate":0,"avgChangeRate":-0.222234},{"month":4,"riseRate":0,"avgChangeRate":-0.102647},{"month":5,"riseRate":1,"avgChangeRate":0.424463},{"month":6,"riseRate":0.666667,"avgChangeRate":0.308486},{"month":7,"riseRate":0,"avgChangeRate":-0.137509},{"month":8,"riseRate":0,"avgChangeRate":-0.193275},{"month":9,"riseRate":0.666667,"avgChangeRate":0.163579},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.023734},{"month":11,"riseRate":0.666667,"avgChangeRate":0.063859},{"month":12,"riseRate":0.333333,"avgChangeRate":0.183219}],"exchange":"NASDAQ","name":"亘喜生物","nameEN":"Gracell Biotechnologies Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"亘喜生物(GRCL)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供亘喜生物(GRCL)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"亘喜生物,GRCL,亘喜生物股票,亘喜生物股票老虎,亘喜生物股票老虎国际,亘喜生物行情,亘喜生物股票行情,亘喜生物股价,亘喜生物股市,亘喜生物股票价格,亘喜生物股票交易,亘喜生物股票购买,亘喜生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"亘喜生物(GRCL)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供亘喜生物(GRCL)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}